New antidepressants: use in high-risk patients.
This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.
Hale
A S
AS
Department of Academic Psychiatry, St. Thomas' Hospital, London, U.K.
D000367:Age Factors; D000368:Aged; D000928:Antidepressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001549:Benzamides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D003866:Depressive Disorder / Q000150:complications / Q000188:drug therapy* / Q000523:psychology; D004347:Drug Interactions; D004827:Epilepsy / Q000150:complications; D006333:Heart Failure / Q000150:complications; D006801:Humans; D017093:Liver Failure / Q000150:complications; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D011597:Psychomotor Performance / Q000187:drug effects; D051437:Renal Insufficiency / Q000150:complications; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use
D000928:Antidepressive Agents; D001549:Benzamides; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors